Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aurinia Pharmaceuticals ( (AUPH) ) has issued an update.
Aurinia Pharmaceuticals reported a significant increase in financial performance for the third quarter of 2025, with total revenue rising by 8% to $73.5 million. Notably, net product sales of LUPKYNIS grew by 27%, prompting the company to raise its sales guidance for 2025 to between $265 million and $270 million. The company also announced progress in advancing Aritinercept toward clinical studies for two autoimmune diseases, indicating a strategic focus on expanding its treatment portfolio.
The most recent analyst rating on (AUPH) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
Aurinia Pharmaceuticals demonstrates strong financial performance and positive earnings call highlights, contributing to a favorable outlook. However, the stock’s high valuation and technical indicators suggest caution. The absence of corporate events further consolidates the focus on financial and earnings performance.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on developing and commercializing therapies for autoimmune diseases. Its primary product, LUPKYNIS, is the first FDA-approved oral therapy for treating adult patients with active lupus nephritis.
Average Trading Volume: 1,769,686
Technical Sentiment Signal: Buy
Current Market Cap: $1.73B
For a thorough assessment of AUPH stock, go to TipRanks’ Stock Analysis page.